Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Molecules to Malady > Compounds to Remember > Flashcards

Compounds to Remember Flashcards

1
Q

RAG1/2

A

recognizes RSS sequence and cleaves it (as a complex with HMG1)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

HMG1

A

chromatin-binding protein (binds with RAG1/2) - required for rearrangement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Artemis

A

A nuclease that cleaves the hairpin structure of the coding joint (as a complex with Ku70,80/DNA-PKcs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Ig alpha/beta

A

scaffolding protein for pre-BCR and BCR - required for successful signalling of rearrangement into the cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

TdT

A

unique to B cells; non-template, random addition of nucleotides to the end of the coding joint

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

ADA

A

an enzyme responsible for differentiation in early precursors of lymphovytes; deficiency leads to ADA-SCID (T- B- NK-)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

BLNK

A

an adaptor protein; required for successful signalling of rearrangement into the cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Syk and Btk

A

kinases; required for successful signalling of rearrangement into the cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

TRECS/KRECS

A

biproduct of succesful VDJ rearrangement in T/B cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

IVIg

A

purified IgG from pooled human sera (>1000 donors) using alcohol fractionation; dose is 400-600mg/kg per month in clinic; 2-4 hours per infusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

SCIg

A

Self-administered weekly subcutaneously via small pump; avoid peak/throughs of IVIg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

CXCR5

A

chemokine receptor expressed by T cells that is upregulated after encountering antigen in lymphoid organ

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

CCR7

A

chemokine receptor expressed by B cells that is upregulated after encountering antigen in lymphoid organ

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

AID enzyme

A
  • introduces nicks into the S DNA region of teh constant region of Ig gene (converting C to U bases) - creating double-stranded breaks
  • introduces point mutations into V genes of GC B cells; important for somatic hypermutation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

gp120

A

viral prtoein expressed by HIV that binds to CD4 in T cells to mediate viral entry; gp120/CD4 complex binds to CCR5/CXCR4 on host cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Collagen/fibronectin

A

produced by Type A synoviocytes; contribute to structural framework of synovial interstitium and cell adherence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Hyaluronan

A

produced by Type A synoviocytes; high MW polysaccharide that maintains synovial fluid viscosity; procides shock absorption

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Lubricin

A

mucin-like proteoglycan; protects cartilage surfaces from deposition and cell adhesion; inhibits synovial cell overgrowth

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

MMPs

A

matrix-metalloproteinases; degrades cartilage; produced by type B synoviocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

IL-17

A

pro-inflammatory cytokine expressed by TH17 cells, induces expression of other pro-inflammatory cytokines and RANKL in other cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

TNF-alpha

A

expressed by activated macrophages, type B synoviocytes, and T cells; induces pro-inflammatory cytokine release, endothelial cell, osteoclast, and chondrocyte activation; angiogenesis

Increases number of osteoclast progenitors and increase expression of RANK and RANKL

Increase expression of DKK, decrease RUNX2 protein levels, alkaline phosphatase and osteocalcin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

IL-1beta

A

inducible form of IL-1; highly pyrogenic and pro-inflammatory; activates leukocytes, endotthelial cells, synovial fibroblasts; induces expression of chemokines, sytokines; induces MMP production by chondrocytes, induces RANKL

produced by type B synoviovytes, macrophages, and endothelail cells, neutrophils

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

IL-6

A

pro-inflammatory cytokine, involved in fever and acute phase response; induce Ig production in B cells, induce differentiation of TH17 cells and osteoclast (RANKL induction), induce cytokine production

produces by macrophages, type B synoviocytes, and T cells

24
Q

STAT3

A

phosphorylation by JAK receptors - leads to promotion of cytokine expression, supresses type B synoviocytes apoptosis; promote T cell survival, promote antibody production; promotes RANKL expression

25
RF
Rheumatoid factor; high-affinity autoantibody against Fc portion of IgG; prior to RA onset, an increase in IgM/IgA
26
DRB1 gene
encodes for HLA-DR antigen presenting molecule, allelic variants DRB1\*0401/0404 most associated with RA
27
PADI
peptidyl-arginine deiminase; respondible for post-translational conversion of the amino acid arginine to citrulline (citrullination); PADI2/4 abundant in RA
28
ACPA
antibodies against citrullinated 'self-proteins'; detected via anti-CCP assay; prior to RA onset, increase in SE spreasing and isotype changes
29
Hydroxypatite
Indoluble salt of calcium and phosphorus
30
RANKL
member of TNF family ligand - mostly membrane-bound but can be cleaved to a soluble form induce osteoclast differentiation and activation; produced normally by osteoblasts and osteocytes produced in RA mostly by type B fibroblasts, osteoblasts, T cells
31
RANK
receptor for RANKLS, expressed on osteoclasts and its precursors
32
Osteoprotegerin
member TNF-receptor family, binds RANKL (acts as decoy receptor); blocls RANKL-induces osteoclast differentiation and activation Normally, produced by osteoblasts
33
34
IL-1
pro-inflammatory cytokine; promotes cell fusion of the mononuclear precursor cells and survival of mature osteoclast
35
Alkaline phosphatase
renders osteoid competent for mineral deposition
36
DKK
Wnt signalling antagonist; inhibition of Wnt signalling leading to inhibtion of osteoblast amturation and bone formation; expression increase by TNF
37
Methotrexate
a csDMARD, anti-metabolite, weekly oral dose; anchor drug, inital DMARD choice in majority of patient Adverse effect: hepatotoxicity, myelotoxicity
38
Sulfasalazine
a csDMARD, anti-inflammatory and anti-microbial; twice daily oral dose Side effect: hepatotoxicity, myelotoxicity
39
Hydroxycloroquine
a csDMARD; daily oral dose - side effect: retinopathy
40
Leflunomide
csDMARD, anti-metabolite; daily oral dose; side effects: hepatotoxicity, myelotoxicity, and hypertension
41
Adalimumab
Hman monoclonal antibody (IgG1); TNF inhibitor Side effect: injection site reations, infections
42
Infliximab
chimeric antibody, huan IgG1 constant region and mouse vairbale region, anti-TNF Side effect: injection site reations, infections
43
Etanercept
fusion protein: two p75 TNF-alpha receptors and human IgG1 constant region
44
Certolizumab pegol
humanised monoclonal antibody (anti-TNF), bound to polyethylene glycol (PEG) Not inferior to ADA (when combined with MTX) in MTX-IR Side effect: injection site reations, infections
45
Golimumab
human IgG1 monoclonal antibody against TNF Side effect: injection site reations, infections
46
Abatacept
T-cell costimulation blocker; formed by CTLA4 molule dimerized on an Ig frame non-inferior to ADA (ADA has more injection site reactions) in MTX-IR, b-DMARD naiive Side effect: injection site reations, infections
47
Anankira
IL-1R antagonist Side effect: injection site reations, infections
48
Rituximab
Chimeric monoclonal antibody (anti-CD20) leads to B cel depletion; doesn't target B cells before Pre-B cell or after Memory B cell in the differentiation phases non-inferior to ADA/ETA (more cost saving) in sero+ve, naiive RA patients Side effect: injection site reations, infections
49
Tocilizumab
Humaized monoclonal antibody against IL-6R Superior to ADA (but associated with more AE) in MTX-IR Side effect: injection site reations, infections, elevated LDL, cytopenias(decrease in platelets and neutrophils)
50
Sarilumab
human IgG1 monoclonal antibody against IL-6R (soluble and membrane-bound) Monotherapy was superior to ADA Side effect: injection site reations, infections, neutropenia
51
JAK1/2
role in growth, neurodevelopment, haematopoesis, host defense
52
JAK3 and Tyk2
engaged in immune responses
53
Tofacitinib
oral JAK inhibitor; preferentially inhibit JAK1/3 limiting T cel and other leukocyte recruitment - decrease in synovial inflammation and structural damage adverse effect: headaches, infection, elevated LDL. neutropenia
54
Baricitinib
Reversible inhibitor of JAK1/2 Side effects: neutropenia, increase in creatinine and LDL, infection risk, malignancy risk?
55
Upadacitinib
Selective inhibitor of JAK1 Adverse reactions: infection, headache, pulmonary embolism

Molecules to Malady (17 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions